CD8A and ovarian carcinoma: The use of the relative T and B/plasma cell content as a biomarker has not yet been investigated in many major solid tumors [35], the exception being ovarian cancer where Kroeger et al. demonstrated that CD8+ TILs carried the most evident prognostic benefit only in the presence of plasma cells and CD20+ TILs [25].